Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients (HEVRO)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03476616 |
|
Recruitment Status : Unknown
Verified August 2018 by Konstantinos Tsioufis, Hippocration General Hospital.
Recruitment status was: Not yet recruiting
First Posted : March 26, 2018
Last Update Posted : August 3, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hypertension Obesity | Drug: Eplerenone (-based therapy) arm Drug: Valsartan (-based therapy) arm | Phase 4 |
The present study plans to enroll obese patients (BMI= 30-40 kg/m2) of 30-75 years of age, with untreated or never-treated essential hypertension to either eplerenone-based or valsartan-based therapy Patients visiting hypertension center(s), eligible to participate in the study and meeting study's inclusion criteria, will at first thoroughly be informed of study's protocol rationale, including scheduled follow-up visits. There will be a period of 2-4 weeks, at which medical history will be taken, as well as somatometrics, including height, weight, BMI and waist circumference. Moreover, a thorough clinical examination will take place, including office blood pressure, ECG, heart-echo, renal ultrasound, blood and urine ultrasound. All women of gestational age should have pregnancy test.
At randomization visit, patients still meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 weeks. At 8, 16 and 24 weeks, patients at both arms will be evaluated with ambulatory BP measurements primary, as well as home and office BP measurements. At week 8, patients with controlled hypertension (mean ambulatory blood pressure measurement (ABPM) <130/80mmHg), will continue in monotherapy with eplerenone or valsartan and patients with uncontrolled hypertension (mean 24-h ambulatory≥130/80mmHg) will continue with the addition of calcium-channel blocker, amlodipine (C) 5 mg od. At week 16, patients achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in patients not achieving blood pressure target, a third drug, thiazide-like-diuretic will be added [indapamide (D) 1.25 mg od]. All groups at both arms will be finally evaluated at 24 weeks.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 330 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial |
| Estimated Study Start Date : | September 1, 2018 |
| Estimated Primary Completion Date : | September 1, 2020 |
| Estimated Study Completion Date : | September 1, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Eplerenone (-based therapy) arm
Obese pts with hypertension, starting treatment with eplerenone 25mg twice daily (BD). ABPM wil be scheduled at wks 8, 16 and 24. At wk 8 if mean ABPM < 130/80mm Hg will continue to monotherapy with eplerenone. If not controlled (mean ABPM > 130/80mm Hg) at wk8, amlodipine 5mg OD will be added. At wk 16 if mean ABPM < 130/80mm Hg will continue to monotherapy with eplerenone, or dual therapy with eplerenone and amlodipine. If not controlled (mean ABPM > 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks. |
Drug: Eplerenone (-based therapy) arm
At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM <130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added [indapamide (D) 1.25 mg od]. All groups at both arms will be evaluated at 24 wks by ABPM. |
|
Active Comparator: Valsartan (-based therapy) arm
Obese pts with hypertension, starting treatment with valsartan 160mg once daily (OD). ABPM wil be scheduled at wks 8, 16 and 24. At wk 8 if mean ABPM < 130/80mm Hg will continue to monotherapy with valsartan. If not controlled (mean ABPM > 130/80mm Hg) at wk8, amlodipine 5mg OD will be added. At wk 16 if mean ABPM < 130/80mm Hg will continue to monotherapy with valsartan, or dual therapy with valsartan and amlodipine. If not controlled (mean ABPM > 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks. |
Drug: Valsartan (-based therapy) arm
At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM <130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added [indapamide (D) 1.25 mg od]. All groups at both arms will be evaluated at 24 wks by ABPM. |
- Difference in change of ABPM from baseline, in the eplerenone arm versus the valsartan arm as monotherapy at 8 weeks, as combined dual treatment with amlodipine at 16 weeks and as combined triple treatment with amlodipine and indapamide at 24 weeks. [ Time Frame: 8, 16 and 24 weeks ]Ambulatory blood pressure measurements (metric unit: mmHg) at baseline and 8,16 and 24 weeks and evaluation of the difference of mean ambulatory systolic and diastolic blood pressure measurements between baseline and each time frame in all participants
- Difference in change of office BP from baseline, in the eplerenone arm versus the valsartan arm as monotherapy at 8 weeks, as combined dual treatment with amlodipine at 16 weeks and as combined triple treatment with amlodipine and indapamide at 24 weeks. [ Time Frame: 8, 16 and 24 weeks ]Office blood pressure measurements (metric unit: mmHg) at baseline and 8,16 and 24 weeks and evaluation of the difference of office systolic and diastolic blood pressure measurements between baseline and each time frame in all participants
- Difference in frequency of controlled hypertension (mean ABPM < 130/80 mm Hg) between the study arms at 8, 16 and 24 weeks. [ Time Frame: 8, 16 and 24 weeks ]Ambulatory blood pressure monitoring (metric unit: mmHg) at baseline and 8,16 and 24 weeks and evaluation of the difference of mean ambulatory systolic and diastolic blood pressure measurements between baseline and each time frame in all participants
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 30 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 30-75 years of age
- Written consent
- Untreated or never-treated arterial hypertension with office systolic blood pressure of 140-180 mmHg and/or diastolic blood pressure of 90-120 mmHg, confirmed by 24-hour ambulatory blood pressure measurements of mean ambulatory systolic blood pressure over 130 mmHg and/or mean ambulatory diastolic blood pressure over 80 mmHg
- Obesity, confirmed estimated by Body Mass Index (BMI) of 30-40 kg/m2
Exclusion Criteria
- Age <30 or >75
- Inability to give informed consent
- Participation in a clinical study involving an investigational drug or device within 4 weeks of screening
- Secondary hypertension
- Recent (<6 months) cardiovascular event requiring hospitalization (eg. myocardial infarction or stroke)
- Type 1 diabetes
- Chronic kidney disease assessed by Estimated Glomerular Filtration Rate (eGFR) <45 mL/min
- Bilateral renal arteries stenosis
- Addison's disease
- Hemodynamically significant valvular heart disease
- Plasma potassium outside of normal range on two successive measurements during screening
- Pregnancy, planning to conceive or women of childbearing potential, that is, not using effective contraception
- Scheduled surgery or cardiovascular surgery over the next 6 months
- Absolute contra-indication to study drugs (eg. asthma) or previous intolerance of trial therapy
- History of sustained atrial fibrillation
- Requirement for study drug for reason other than to treat hypertension, (eg, β-blockers for angina or aldosterone antagonists for heart failure)
- Neoplasm under treatment (radiotherapy / chemotherapy / immunotherapy)
- Any concomitant condition that, in the opinion of the investigator, may adversely affect the safety and/or efficacy of the study drug or
- severely limit that patients' life-span or ability to complete the study (eg, alcohol or drug abuse, disabling or terminal illness, mental
- disorders)
- Contemporary systemic disease with life expectancy shorter than the end of the study
-
Treatment with any of the following medications:
- Oral corticosteroids within 3 months of screening. Treatment with systemic corticosteroids is also prohibited during study participation
- Chronic stable use, or unstable use of NSAIDs (other than low dose aspirin) is prohibited. Chronic use is defined as >3 consecutive or non-consecutive days of treatment per week. In addition, intermittent use of NSAIDs is strongly discouraged throughout the study and NSAIDs if required, must not be used for more than a total of 2 days. For those requiring analgesics during the study, paracetamol is recommended.
- The use of short-acting nitrates (eg, sublingual nitroglycerin) is permitted.
- The use of sympathomimetic decongestants is permitted, however, not within 1 day prior to any study visit/BP assessment
- The use of theophylline is permitted but the dose must be stable for at least 4 weeks prior to screening and throughout the study;
- The use of phosphodiesterase type V inhibitors is permitted; however, study participants must refrain from taking these medications for at least 1 day prior to screening or any subsequent study visits
- The use of α-blockers is not permitted, with the exception of alfuzosin and tamsulosin for prostatic symptoms
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03476616
| Contact: Konstantinos P Tsioufis, Ass. Prof. | 6932586087 ext +30 | ktsioufis@hippocratio.gr | |
| Contact: Panayiotis P Iliakis, MD | 6937489286 ext +30 | panayiotisiliakis@gmail.com |
| Greece | |
| Hypertension Unit, First Cardiology Clinic, Hippocration General Hospital, University of Athens, Athens, Greece | |
| Athens, Greece, 11527 | |
| Contact: Konstantinos P Tsioufis, Ass. Prof. 6932586087 ext +30 ktsioufis@hippocratio.gr | |
| Contact: Panayiotis P Iliakis, MD 6937489286 ext +30 panayiotisiliakis@gmail.com | |
| Principal Investigator: Konstantinos P Tsioufis, Ass. Prof. | |
| Sub-Investigator: Kyriakos S Dimitriadis, MD, PhD | |
| Sub-Investigator: Panayiotis P Iliakis, MD | |
| Principal Investigator: | Konstantinos P Tsioufis, Ass. Prof. | Hypertension Unit, First Cardiology Clinic, Hippocration General Hospital, University of Athens, Greece |
| Responsible Party: | Konstantinos Tsioufis, Principal Investigator. Assoc. Prof. Konstantinos P.Tsioufis, MD, PhD, FESC, FACC, Associate Professor of Cardiology, Head of Hypertension Unit, ESH Excellesh center, Hippocration General Hospital |
| ClinicalTrials.gov Identifier: | NCT03476616 |
| First Posted: | March 26, 2018 Key Record Dates |
| Last Update Posted: | August 3, 2018 |
| Last Verified: | August 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Hypertension Obesity Ambulatory Blood Pressure Eplerenone |
Valsartan Mineralocorticoid Receptor Antagonists Angiotensin II Receptor Blockers |
|
Hypertension Vascular Diseases Cardiovascular Diseases Valsartan Eplerenone Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists |
Molecular Mechanisms of Pharmacological Action Mineralocorticoid Receptor Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Diuretics, Potassium Sparing Diuretics Natriuretic Agents |